Stock CRDL CARDIOL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cardiol Therapeutics Inc.

Equities

CRDL

CA14161Y2006

Market Closed - Toronto S.E.
Other stock markets
 21:00:00 27/06/2024 BST 		5-day change 1st Jan Change
2.74 CAD -1.79% Intraday chart for Cardiol Therapeutics Inc. +7.03% +149.09%
06-26 ROTH MKM Initiates Coverage on Cardiol Therapeutics With Buy Rating, $10 Price Target MT
06-13 Sector Update: Health Care Stocks Ease Late Afternoon MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cardiol Therapeutics Inc. : Cardiol Therapeutics überträgt virtuelle Jahreshaupt- und Sonderversammlung der Aktionäre am 26. Juni um 16:30 Uhr EDT im Internet
Cardiol Therapeutics Inc (von First Berlin Equity Research...
Sector Update: Health Care Stocks Ease Late Afternoon
Sector Update: Health Care Stocks Softer Thursday Afternoon
Cardiol Therapeutics Shares Fall After Report or Phase II Data for CardiolRx in Recurrent Pericarditis
Cardiol Therapeutics Inc. : Cardiol Therapeutics veröffentlicht positive Topline-Daten aus seiner Phase-II-Pilotstudie MAvERIC zur Beurteilung von CardiolRx bei wiederkehrender Perikarditis
Cardiol Therapeutics Inc. Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx? for Recurrent Pericarditis
Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure
Cardiol Therapeutics Inc. : Cardiol Therapeutics präsentiert seine Phase-II-Studie ARCHER beim World Congress on Acute Heart Failure 2024
Cardiol Therapeutics Inc. Presents Phase II Archer Trial at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics Inc. : Cardiol Therapeutics gibt Update zur Geschäftstätigkeit zum Jahresende 2023 bekannt
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cardiol Therapeutics Inc (von First Berlin Equity Research...
Cardiol Therapeutics Inc. : Cardiol Therapeutics schließt in seiner Phase-II-Pilotstudie MAvERIC zur Bewertung von CardiolRx bei wiederkehrender Perikarditis die Patientenrekrutierung ab
Cardiol Therapeutics Inc. Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx? for Recurrent Pericarditis
Cardiol Therapeutics Receives Orphan Drug Designation From FDA for Lead Drug Candidate to Treat Pericarditis
Cardiol Therapeutics Inc. : Cardiol Therapeutics erhält für seinen Hauptwirkstoffkandidaten zur Behandlung der Perikarditis die Zulassung als Orphan-Arzneimittel
Cardiol Therapeutics Inc (von First Berlin Equity Research...
Cardiol Therapeutics Enrolls Over 50% of Patients for Phase II ARCHER Trial in Acute Myocarditis
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRDL Stock
  4. News Cardiol Therapeutics Inc.
  5. Other languages